(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
24 June 2021 (24.06.2021)

WIPO | PCT

(10) International Publication Number
WO 2021/127539 A1

(51) International Patent Classification:
C07D 405/12 (2006.01) *A61K 31/5377* (2006.01)
A61P 35/00 (2006.01)

(21) International Application Number:
PCT/US2020/066176

(22) International Filing Date:
18 December 2020 (18.12.2020)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
62/951,842 20 December 2019 (20.12.2019) US

(71) Applicant: **EPIZYME, INC.** [US/US]; 400 Technology Square 4th Floor, Cambridge, Massachusetts 02139 (US).

(72) Inventors: **VERWIJS, Marinus Jacobus**; 22 East Street, Sudbury, Massachusetts 01776 (US). **AM ENDE, David Jon**; 39 Jeremy Drive, East Lyme, Connecticut 06333 (US). **ANDERSON, Stephen Richard**; 57 Whittaker Drive, Stonington, Connecticut 06378 (US). **BEEVERS, Andrew Paul George**; 58, North Road, Chester-le-Street, Durham DH3 4AJ (GB). **BREAULT, Mark Kenneth**; 52 Essex Street, Apt. 6B, Deep River, Connecticut 06417 (US). **TUDHOPE, Stephen Richard**; 3 Redhill, Sunderland SR6 7JX (GB). **WOLSTENHULME, Jamie Ross**; 5 Fern Avenue, Cramlington NE23 3GL (GB).

(74) Agent: **ERLACHER, Heidi A.** et al.; 1299 Pennsylvania Ave., Suite 700, Washington, District of Columbia 20004 (US).


(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:
— *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*

Published:
— *with international search report (Art. 21(3))*

(54) Title: CRYSTALLINE HYDROBROMIDE SALT OF A EZH2 INHIBITOR, ITS PREPARATION AND PHARMACEUTICAL COMPOSITION USEFUL FOR THE TREATMENT OF CANCER



(Compound I hydrobromide)

(57) Abstract: The application relates to a crystalline form of N-((4,6-dimethyl-2- oxo-l,2-dihydropyridin-3-yl)methyl)-5-(ethyl (tetrahydro-2H- pyran-4-yl)amino)-4-methyl-4'-(morpholinomethyl)-[1,1'-biphenyl]-3- carboxamide (Tazemetostat) hydrobromide, to methods for its preparation, and to pharmaceutical compositions comprising it. The compound is known to be an effective inhibitor of EZH2 (Enhancer of Zeste homologue 2) useful for the treatment of cancer.

WO 2021/127539 A1